Assay Detail
Binding
CHEMBL4361889
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Protac activity at VHL/IRAK4 in human PBMC assessed as reduction in R848-stimulated IL-6 level preincubated for 18 hrs followed by R848 stimulation and measured after 8 hrs by MSD assay
2
Total Activities
2
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Confidence | 5 — Multiple protein complex / RNA |
| Curated By | Autocuration |
Target
von Hippel-Lindau disease tumor suppressor/IRAK4 (CHEMBL4523742) ↗| Type | PROTEIN-PROTEIN INTERACTION |
| Organism | Homo sapiens |
Publication
Targeting IRAK4 for Degradation with PROTACs.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 2 | 7.35 | 7.50 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL4081711 | ZIMLOVISERTIB | 2.0 | 1 | 7.50 |
| CHEMBL4521789 | — | — | 1 | 7.20 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL4081711 | ZIMLOVISERTIB | IC50 | = | 31.62 | nM | 7.50 |
| CHEMBL4521789 | — | IC50 | = | 63.1 | nM | 7.20 |